RESEARCH MONOGRAPH · KDC-MN-150

Suvorexant

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

The first dual orexin antagonist that proved the class works, with a half-life thats clinically awkward

Suvorexant (Belsomra) was Merck's first-in-class dual orexin receptor antagonist, approved in 2014 for insomnia. It binds both OX1R and OX2R with similar affinity in the low nanomolar range, with the OX2R blockade being the part that matters most for sleep onset and maintenance (the OX2R-expressing histaminergic neurons in the tuberomammillary nucleus are the key downstream node for wake-promotion).

The clinical efficacy in the registration trials was modest but real. Improvements in sleep onset latency of around 5 to 10 minutes versus placebo, improvements in wake-after-sleep-onset of around 15 to 25 minutes. Not dramatic on point estimates but meaningfully different mechanistically from the benzodiazepine receptor agonists (zolpidem, eszopiclone) because you're not allosterically modulating GABA-A and therefore not getting the abuse liability, tolerance development, and morning hangover profile that BZRAs are known for.

What we like: the mechanism is fundamentally different from existing sleep aids and addresses what looks like the right biology. Orexin loss causes narcolepsy with cataplexy in humans, so partial orexin blockade is a coherent way to promote sleep without the GABA-A confounds. As a research tool for orexin pharmacology its useful. The safety profile in the trials was clean (no respiratory depression, minimal abuse signal).

What we dont like: the half-life is 12 hours, which is long enough that morning residual effects (drowsiness, slowed reaction time, occasional reports of sleep paralysis-like phenomena) are real clinical issues. The newer dual orexin antagonist lemborexant has a shorter half-life and a slightly cleaner profile in head-to-head practical terms. Suvorexant got first-mover advantage but the molecule isnt the optimal entry in the class.

Mechanism: well-mapped at the OX1R/OX2R level. Downstream effects on histaminergic, noradrenergic, and cholinergic wake-promoting systems are characterized through the orexin receptor distribution literature.

Sourcing: novel small molecule, branded pharmaceutical, research-grade is available from major chemical suppliers and is reasonably characterized. Verify chiral purity if you care about that.

Real biology, modest effect size, marketed past where the data sits. The class is genuinely interesting; this particular molecule is fine but not the best one.

Evidence: 80
Mechanism: 85
Reliability: 70
Safety: 75
Sourcing: 70
Value: 50
Signal: 60
Staying power: 65

Plain-language summary Intrigue 78 / 100

Suvorexant, sold as Belsomra, is a dual orexin receptor antagonist (DORA), the first of a new sleep medication class. Unlike GABAergic hypnotics it works by blocking the wakefulness-promoting orexin system. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Dual orexin receptor antagonist

A dual orexin receptor antagonist (DORA) FDA-approved as Belsomra for insomnia, the first commercialized of the DORA class.

Abstract

Suvorexant (Belsomra; MK-4305; CAS 1030377-33-3; molecular formula C23H23ClN6O2; molecular weight 450.92) is a dual orexin receptor (OX1R, OX2R) antagonist developed by Merck and approved by the FDA in 2014 for insomnia. The compound was the first commercialized DORA. Mechanism is competitive antagonism at orexin-A (hypocretin-1) and orexin-B (hypocretin-2) binding sites on OX1R and OX2R, attenuating orexinergic wakefulness signaling without GABAergic hypnotic effects. Pharmacokinetics: plasma half-life 12 hours; CYP3A4 metabolism. Reported research dose ranges in the literature are described in the source publications. Schedule IV.

Mechanism of action

Dual orexin receptor (OX1R, OX2R) antagonist. No GABAergic activity. Distinct from benzodiazepine and Z-drug hypnotics.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Herring WJ, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 2016.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-150

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Suvorexant

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs